Etomidate-induced myoclonus
Conditions
Interventions
Group S (0 mg/kg oliceridine, equivalent volume of normal saline):In the control group, an equal volume of normal saline was intravenously administered 3 minutes before etomidate injection, to compare
Group A1 (0.01 mg/kg oliceridine):Oliceridine (0.01 mg/kg IV) was administered 3 minutes prior to etomidate injection to evaluate its modulatory effects on etomidate-induced myoclonus.
Group A2 (0.02 mg/kg oliceridine):Oliceridine (0.02 mg/kg IV) was administered as a pretreatment 3 minutes before etomidate injection to systematically evaluate its efficacy in attenuating etomidate-i
Sponsors
The First Affiliated Hospital of Xiamen University
Eligibility
Sex/Gender
All
Age
19 Years to 65 Years
Inclusion criteria
Inclusion criteria: Aged 19-65 years, classified as American Society of Anesthesiologists (ASA) physical status I or II.
Exclusion criteria
Exclusion criteria: Neuromuscular conduction-disorder diseases; allergy to study medications (etomidate, oliceridine, or remifentanil); diagnosis of epilepsy; recent upper respiratory tract infection (within 14 days); severe dysfunction of vital organs; uncontrolled hypertension (blood pressure > 180/110 mmHg); obesity(BMI>30kg/m^2); predicted difficult airway management; chronic use of psychotropic medications or cognitive impairment; inability to cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myoclonus incidence and severity; | — |
Secondary
| Measure | Time frame |
|---|---|
| MAP;Injection pain;HR;SpO2 ;Endoscopist satisfaction;Patient satisfaction with the gastroscopy experience;Nausea-vomiting; | — |
Countries
China
Contacts
Public ContactYingchuan Lin
The First Affiliated Hospital of Xiamen University
Outcome results
None listed